390 related articles for article (PubMed ID: 29776968)
21. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
Burcelin R; Gourdy P
Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
[TBL] [Abstract][Full Text] [Related]
22. Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein.
Zhou W; Shao W; Zhang Y; Liu D; Liu M; Jin T
Am J Physiol Endocrinol Metab; 2020 Sep; 319(3):E568-E578. PubMed ID: 32723174
[TBL] [Abstract][Full Text] [Related]
23. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
Jensterle M; Pirš B; Goričar K; Dolžan V; Janež A
Eur J Clin Pharmacol; 2015 Jul; 71(7):817-24. PubMed ID: 25991051
[TBL] [Abstract][Full Text] [Related]
24. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
[TBL] [Abstract][Full Text] [Related]
25. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
Silver HJ; Olson D; Mayfield D; Wright P; Nian H; Mashayekhi M; Koethe JR; Niswender KD; Luther JM; Brown NJ
Diabetes Obes Metab; 2023 Aug; 25(8):2340-2350. PubMed ID: 37188932
[TBL] [Abstract][Full Text] [Related]
26. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Killion EA; Wang J; Yie J; Shi SD; Bates D; Min X; Komorowski R; Hager T; Deng L; Atangan L; Lu SC; Kurzeja RJM; Sivits G; Lin J; Chen Q; Wang Z; Thibault SA; Abbott CM; Meng T; Clavette B; Murawsky CM; Foltz IN; Rottman JB; Hale C; Véniant MM; Lloyd DJ
Sci Transl Med; 2018 Dec; 10(472):. PubMed ID: 30567927
[TBL] [Abstract][Full Text] [Related]
27. Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation.
Costa A; Ai M; Nunn N; Culotta I; Hunter J; Boudjadja MB; Valencia-Torres L; Aviello G; Hodson DJ; Snider BM; Coskun T; Emmerson PJ; Luckman SM; D'Agostino G
Mol Metab; 2022 Jan; 55():101407. PubMed ID: 34844019
[TBL] [Abstract][Full Text] [Related]
28. GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
Kadouh H; Chedid V; Halawi H; Burton DD; Clark MM; Khemani D; Vella A; Acosta A; Camilleri M
J Clin Endocrinol Metab; 2020 May; 105(5):1552-63. PubMed ID: 31665455
[TBL] [Abstract][Full Text] [Related]
29. The locus coeruleus contributes to the anorectic, nausea, and autonomic physiological effects of glucagon-like peptide-1.
Fortin SM; Chen JC; Petticord MC; Ragozzino FJ; Peters JH; Hayes MR
Sci Adv; 2023 Sep; 9(38):eadh0980. PubMed ID: 37729419
[TBL] [Abstract][Full Text] [Related]
30. Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators.
Decara J; Arrabal S; Beiroa D; Rivera P; Vargas A; Serrano A; Pavón FJ; Ballesteros J; Dieguez C; Nogueiras R; Rodríguez de Fonseca F; Suárez J
Biofactors; 2016 Nov; 42(6):600-611. PubMed ID: 27213962
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
[No Abstract] [Full Text] [Related]
32. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
33. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
Pastel E; McCulloch LJ; Ward R; Joshi S; Gooding KM; Shore AC; Kos K
Clin Sci (Lond); 2017 Mar; 131(5):343-353. PubMed ID: 28049736
[TBL] [Abstract][Full Text] [Related]
34. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
Tzotzas T; Karras SN; Katsiki N
Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
[TBL] [Abstract][Full Text] [Related]
35. GLP-1 physiology informs the pharmacotherapy of obesity.
Drucker DJ
Mol Metab; 2022 Mar; 57():101351. PubMed ID: 34626851
[TBL] [Abstract][Full Text] [Related]
36. The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat.
Hansen HH; Hansen G; Paulsen S; Vrang N; Mark M; Jelsing J; Klein T
Eur J Pharmacol; 2014 Oct; 741():254-63. PubMed ID: 25160746
[TBL] [Abstract][Full Text] [Related]
37. GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice.
Kumari P; Nakata M; Zhang BY; Otgon-Uul Z; Yada T
Biochem Biophys Res Commun; 2018 May; 499(3):618-625. PubMed ID: 29601817
[TBL] [Abstract][Full Text] [Related]
38. Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice.
Burmeister MA; Ferre T; Ayala JE; King EM; Holt RM; Ayala JE
Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E334-43. PubMed ID: 22094469
[TBL] [Abstract][Full Text] [Related]
39. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.
Liskiewicz A; Khalil A; Liskiewicz D; Novikoff A; Grandl G; Maity-Kumar G; Gutgesell RM; Bakhti M; Bastidas-Ponce A; Czarnecki O; Makris K; Lickert H; Feuchtinger A; Tost M; Coupland C; Ständer L; Akindehin S; Prakash S; Abrar F; Castelino RL; He Y; Knerr PJ; Yang B; Hogendorf WFJ; Zhang S; Hofmann SM; Finan B; DiMarchi RD; Tschöp MH; Douros JD; Müller TD
Nat Metab; 2023 Dec; 5(12):2075-2085. PubMed ID: 37946085
[TBL] [Abstract][Full Text] [Related]
40. FGF21 signaling in glutamatergic neurons is required for weight loss associated with dietary protein dilution.
Flippo KH; Jensen-Cody SO; Claflin KE; Potthoff MJ
Sci Rep; 2020 Nov; 10(1):19521. PubMed ID: 33177640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
